<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lidocaine and tetracaine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lidocaine and tetracaine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lidocaine and tetracaine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10241" href="/d/html/10241.html" rel="external">see "Lidocaine and tetracaine: Drug information"</a> and <a class="drug drug_patient" data-topicid="11983" href="/d/html/11983.html" rel="external">see "Lidocaine and tetracaine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F1181967"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Pliaglis;</li>
<li>Synera [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52912125"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Pliaglis</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F3300077"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Analgesic, Topical</span>;</li>
<li>
<span class="list-set-name">Local Anesthetic, Topical</span></li></ul></div>
<div class="block dop drugH1Div" id="F1181994"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f4a77419-4151-4000-ae49-2910090aec84">Anesthesia, topical</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anesthesia, topical:</b> Children ≥3 years and Adolescents: Patch:</p>
<p style="text-indent:-2em;margin-left:4em;">Venipuncture or IV cannulation: Prior to procedure, apply to intact skin for 20 to 30 minutes. <b>Note:</b> May use another patch at a new location to facilitate venous access after a failed attempt; remove previous patch. Otherwise, simultaneous or sequential application of multiple patches is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Superficial dermatologic procedures: Prior to procedure, apply to intact skin for 30 minutes.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51117795"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Lidocaine primarily undergoes hepatic metabolism and its pharmacokinetics are not expected to be changed significantly following topical administration of recommended doses in renal impairment.</p></div>
<div class="block dohp drugH1Div" id="F51117796"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Use caution in patients with severe hepatic dysfunction.</p></div>
<div class="block doa drugH1Div" id="F1181995"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10241" href="/d/html/10241.html" rel="external">see "Lidocaine and tetracaine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f4a77419-4151-4000-ae49-2910090aec84">Anesthesia, topical</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Anesthesia, topical: </b></p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Cream:</i> Superficial dermatological procedures: Prior to procedure, apply to intact skin for 20 to 60 minutes. Amount of cream varies depending on size of the surface area to be treated; see manufacturer's labeling for detailed information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Patch: </i></p>
<p style="text-indent:-2em;margin-left:4em;">Venipuncture or intravenous cannulation: Prior to procedure, apply to intact skin for 20 to 30 minutes; <b>Note:</b> May use another patch at a new location to facilitate venous access after a failed attempt; remove previous patch.</p>
<p style="text-indent:-2em;margin-left:4em;">Superficial dermatological procedures: Prior to procedure, apply to intact skin for 30 minutes</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991171"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Lidocaine primarily undergoes hepatic metabolism and its pharmacokinetics are not expected to be changed significantly following topical administration of recommended doses in renal impairment.</p></div>
<div class="block doha drugH1Div" id="F50988556"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Use caution in patients with severe hepatic dysfunction.</p></div>
<div class="block adr drugH1Div" id="F1181978"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Localized blanching (12% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema (47% to 71%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Skin edema (12% to 14%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness (≤1%), drowsiness (≤1%), headache (≤1%), paresthesia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (≤1%), contact dermatitis (≤1%), ecchymosis (≤1%), maculopapular rash (≤1%), skin blister (≤1%), urticaria (≤1%), vesicobullous dermatitis (≤1%), xeroderma (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (≤1%), vomiting (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Petechial rash (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site dermatitis (&lt;4%), application site rash (&lt;4%), local discoloration (&lt;4%), application site pain (≤1%), application-site pruritus (≤1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylactoid shock, angioedema, blepharitis, bronchospasm, burning sensation of skin, confusion, dehydration, diaphoresis, fever, hyperventilation, hypotension, nervousness, pallor, pharyngitis, stupor, syncope, tremor</p></div>
<div class="block coi drugH1Div" id="F1181974"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to lidocaine, tetracaine, amide or ester-type anesthetic agents, para-aminobenzoic acid (PABA), or any other component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Cream: Congenital or idiopathic methemoglobinemia; procedures requiring large amounts over large areas of the body (&gt;400 cm<sup>2</sup>).</p></div>
<div class="block war drugH1Div" id="F1181975"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity or anaphylactic reactions, including angioedema, bronchospasm, shock, and urticaria, may occur. Discontinue use and institute appropriate therapy if hypersensitivity occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants &lt;6 months are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, lightheadedness, fatigue).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Other local anesthetics: If being used with other products containing local anesthetic, consider potential for additive effects.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acutely ill patients: Use with caution in acutely ill patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in debilitated patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pseudocholinesterase deficiency: Use with caution in patients with pseudocholinesterase deficiency; greater risk of lidocaine/tetracaine toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Topical cream: Application of cream for longer duration than recommended, or application over larger surface areas is not recommended because of the risk for increased drug absorption and possible adverse reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Transdermal patch: Application of patch for longer duration than recommended, or simultaneous or sequential application of multiple patches is not recommended because of the risk for increased drug absorption and possible adverse reactions. Patch may contain conducting metal (eg, iron); remove patch prior to MRI. Proper storage and disposal of used patches are essential to prevent accidental exposures, especially in children; accidental exposure may result in serious adverse effects.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Avoid contact with eye and lip; loss of protective reflexes may predispose to corneal irritation and/or abrasion. Application to broken or inflamed skin or mucous membranes may lead to increased systemic absorption. Not for use at home. Do not use prior to vaccine injections.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878695"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In a clinical trial, lidocaine/tetracaine cream (Pliaglis) applied for 30 minutes was not shown to be effective at providing venipuncture analgesia in pediatric patients 5 to 17 years. Topical patches and cream (both used and unused) may cause toxicities in children; used patches and cream still contain large amounts of lidocaine and tetracaine; store and dispose out of the reach of children.  </p></div>
<div class="block foc drugH1Div" id="F1182001"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;">Cream, external:</p>
<p style="text-indent:-2em;margin-left:4em;">Pliaglis: Lidocaine 7% and tetracaine 7% (30 g, 100 g [DSC]) [contains methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Lidocaine 7% and tetracaine 7% (30 g [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;">Patch, transdermal:</p>
<p style="text-indent:-2em;margin-left:4em;">Synera: Lidocaine 70 mg and tetracaine 70 mg (10s) [contains heating component, metal; each patch is ~50 cm<sup>2</sup>] [DSC]</p></div>
<div class="block geq drugH1Div" id="F3362805"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes: cream</p></div>
<div class="block fee drugH1Div" id="F16321913"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Pliaglis External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7-7% (per gram): $46.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Pliaglis External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7-7% (per each): $1,400.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F56454989"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;">Cream, external:</p>
<p style="text-indent:-2em;margin-left:4em;">Pliaglis: Lidocaine 7% and tetracaine 7% (30 g) [contains methylparaben, propylparaben]</p></div>
<div class="block admp drugH1Div" id="F52614155"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Topical:</p>
<p style="text-indent:-2em;margin-left:2em;">Topical cream: Apply to intact, healthy skin. Spread self-occluding cream evenly and thinly (approximately 1 mm) across the treatment area using a flat-surfaced tool (eg, metal spatula, tongue depressor). After waiting the required application time, remove the cream by grasping a free-edge with fingers and pulling it away from the skin. Alternatively, the cream may be removed with gauze. If skin irritation or a burning sensation occurs, remove cream. Wash hands after handling cream. Carefully discard the used cream out of the reach of children and pets.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal patch: Apply to intact, healthy skin. Use immediately after opening pouch. Patch begins to heat once removed from pouch. May increase skin temperature by 5°C, will not exceed 40°C. If irritation or burning sensation occurs during application, remove patch. Wash hands after applying. Do not cut the patch or remove the top cover; this could result in thermal injury. Do not cover the holes on the top side of the patch as this could cause the patch not to heat up. Carefully dispose of used patches as they contain large amounts of lidocaine and tetracaine. Fold adhesive together following use.</p></div>
<div class="block adm drugH1Div" id="F1181997"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Topical cream: Apply to intact, healthy skin. Avoid contact with eyes and lips. Prior to procedure, spread self-occluding cream evenly and thinly (approximately 1 mm) across the treatment area using a flat-surfaced tool (eg, metal spatula, tongue depressor). After waiting the required application time, remove the cream by grasping a free-edge with fingers and pulling it away from the skin. Alternatively, the cream may be removed with gauze. Do not apply to the procedure site after the procedure has been performed. If skin irritation or a burning sensation occurs, remove cream. Wash hands after handling cream. Carefully discard the used cream out of the reach of children and pets.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal patch: Apply to intact, healthy skin. Use immediately after opening pouch. Patch begins to heat once removed from pouch. May increase skin temperature by 5°C, will not exceed 40°C. If irritation or burning sensation occurs during application, remove patch. Wash hands after applying. Do not cut the patch or remove the top cover. Do not cover the holes on the top side of the patch. Carefully dispose of used patches as they contain large amounts of lidocaine and tetracaine. Fold adhesive together following use.</p></div>
<div class="block sts drugH1Div" id="F1181987"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Cream: Store refrigerated at 2°C to 8°C (36°F to 46°F); do not freeze.  Stable at room temperature for up to 3 months.</p>
<p style="text-indent:-2em;margin-left:2em;">Patch: Store  at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).</p></div>
<div class="block usep drugH1Div" id="F53569933"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Topical anesthesia of intact skin to provide local analgesia for superficial dermatological procedures (Patch: FDA approved in ages ≥3 years and adults; Cream:  FDA approved in adult)</p></div>
<div class="block mst drugH1Div" id="F11394984"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Transdermal patch may contain conducting metal (eg, iron); remove patch prior to MRI.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F1181984"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F1181983"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antiarrhythmic Agents (Class IB): Lidocaine (Topical) may enhance the adverse/toxic effect of Antiarrhythmic Agents (Class IB). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Lidocaine (Topical).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F1181973"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Systemic absorption following topical application is expected to be low compared to parenteral administration, and is related to duration of exposure and surface area of application site. Systemic absorption would be required in order for lidocaine and tetracaine to cross the placenta and reach the fetus.</p>
<p style="text-indent:0em;margin-top:2em;">Refer to Lidocaine (Systemic), Lidocaine (Topical), and Tetracaine (Systemic) monographs.</p></div>
<div class="block mopp drugH1Div" id="F53569896"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Pain assessment</p></div>
<div class="block pha drugH1Div" id="F1181988"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline"> Local anesthetic action occurs by stabilization of neuronal membranes and inhibiting the sodium ion fluxes required for the initiation and conduction of impulses.</p></div>
<div class="block phk drugH1Div" id="F1181990"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Also see individual agents.</p>
<p style="text-indent:-4em;margin-left:4em;">Onset: Within 20 to 30 minutes</p>
<p style="text-indent:-4em;margin-left:4em;">Duration: Cream: 11 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Related to duration of application and area where applied. </p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Lidocaine crosses the blood-brain barrier</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>: Lidocaine: Neonates: 2.75 L/kg; Adults: 1.1 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Lidocaine: 70%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: </p>
<p style="text-indent:-2em;margin-left:4em;">Lidocaine: Metabolized in the liver by cytochrome P450 CYP1A2 and partially by CYP3A4 to inactive and active metabolites monoethylglycinexylidide (MEGX) and glycinexylidide (GX) </p>
<p style="text-indent:-2em;margin-left:4em;">Tetracaine: Hydrolysis by plasma esterases to primary metabolites para-aminobenzoic acid and diethylaminoethanol  </p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Lidocaine: Adults: 1.8 hours </p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Lidocaine: Excreted in urine as metabolites and parent drug </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038861"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Pliaglis</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Pliaglis | Rapydan</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Pliaglis</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Pliaglis</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Pliaglis</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Pliaglis</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Pliaglis | Rapydan</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Pliaglis</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Lidokaiini/Tetrakaiini Eusa</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Pliaglis</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Pliaglis</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Rapydan</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Litramed</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Pliaglis</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Tetralid | Viveta</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Pliaglis | Ralydan</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Pliaglis</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Pliaglis | Rapydan</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Pliaglis</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Pliaglis</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Pliapel | Rapydan</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Pliaglis | Rapydan</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Lidocaine and tetracaine</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Pliaglis | Rapydan</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Pliaglis</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Rapydan</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Pliaglis (lidocaine and tetracaine) [prescribing information]. Phoenix, AZ: Oba Pharmaceuticals, Inc; September 2020.</div>
</li>
<li>
<div class="reference">
                  Pliaglis (lidocaine and tetracaine) [product monograph]. Laval, Quebec, Canada: Crescita Skin Sciences Inc; November 2021.</div>
</li>
<li>
<div class="reference">
                  Synera (lidocaine and tetracaine) [prescribing information]. Souderton, PA: Galen US Inc; December 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 13027 Version 193.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
